These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

503 related articles for article (PubMed ID: 33958146)

  • 1. Current Therapy for Metastatic Urothelial Carcinoma.
    Nadal R; Clara JA; Valderrama BP; Bellmunt J
    Hematol Oncol Clin North Am; 2021 Jun; 35(3):469-493. PubMed ID: 33958146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antibody-Drug Conjugates in Urothelial Carcinoma: A New Therapeutic Opportunity Moves from Bench to Bedside.
    Ungaro A; Tucci M; Audisio A; Di Prima L; Pisano C; Turco F; Delcuratolo MD; Di Maio M; Scagliotti GV; Buttigliero C
    Cells; 2022 Feb; 11(5):. PubMed ID: 35269424
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Salvage systemic therapy for metastatic urothelial carcinoma: an unmet clinical need.
    Montazeri K; Sonpavde G
    Expert Rev Anticancer Ther; 2021 Mar; 21(3):299-313. PubMed ID: 33249937
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Management of metastatic urothelial carcinoma: Current approach, emerging agents, and future perspectives.
    Iacovelli R; Cicala CM; Ciccarese C; Sacco E; Racioppi M; Bassi PF; Tortora G
    Urologia; 2023 Feb; 90(1):3-10. PubMed ID: 36537831
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Rapidly Evolving Landscape of First-Line Targeted Therapy in Metastatic Urothelial Cancer: A Systematic Review.
    Lavoie JM; Sridhar SS; Ong M; North S; Alimohamed N; McLeod D; Eigl BJ
    Oncologist; 2021 Aug; 26(8):e1381-e1394. PubMed ID: 34028134
    [TBL] [Abstract][Full Text] [Related]  

  • 6. UC Trials Get Standing Ovation.
    Cancer Discov; 2023 Dec; 13(12):2496. PubMed ID: 37916818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biomarker-Oriented Therapy in Bladder and Renal Cancer.
    Scholtes MP; Alberts AR; Iflé IG; Verhagen PCMS; van der Veldt AAM; Zuiverloon TCM
    Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33799514
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Targeted Molecular Therapeutics for Bladder Cancer-A New Option beyond the Mixed Fortunes of Immune Checkpoint Inhibitors?
    Bednova O; Leyton JV
    Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33019653
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Updates and novel treatments in urothelial carcinoma.
    Hanna KS
    J Oncol Pharm Pract; 2019 Apr; 25(3):648-656. PubMed ID: 30304985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The management of toxicities from immune, targeted and ADCs treatments in patients with urothelial cancer.
    Atiq S; Hirshman N; Shariff A; Zhang T
    Urol Oncol; 2023 Oct; 41(10):410-419. PubMed ID: 34973855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Treatment approaches for FGFR-altered urothelial carcinoma: targeted therapies and immunotherapy.
    Benjamin DJ; Hsu R
    Front Immunol; 2023; 14():1258388. PubMed ID: 37675102
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Erdafitinib for the treatment of metastatic bladder cancer.
    Montazeri K; Bellmunt J
    Expert Rev Clin Pharmacol; 2020 Jan; 13(1):1-6. PubMed ID: 31810398
    [No Abstract]   [Full Text] [Related]  

  • 13. The Evolving Landscape of Antibody-Drug Conjugates for Urothelial Carcinoma.
    Abel M; Burkenroad A; Sun A; Lu E; Stefanoudakis D; Drakaki A
    Clin Genitourin Cancer; 2021 Jun; 19(3):183-193. PubMed ID: 33558159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. An update on antibody-drug conjugates in urothelial carcinoma: state of the art strategies and what comes next.
    D'Angelo A; Chapman R; Sirico M; Sobhani N; Catalano M; Mini E; Roviello G
    Cancer Chemother Pharmacol; 2022 Sep; 90(3):191-205. PubMed ID: 35953604
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Updates in the management and future landscape of urothelial carcinoma.
    Hanna KS; Campbell M; Kolling A; Husak A; Sturm S; Bello D; Blake K
    J Oncol Pharm Pract; 2021 Mar; 27(2):435-444. PubMed ID: 33143526
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Research progress on PD-1 and PD-L1 inhibitors in the treatment of metastatic urothelial carcinoma.
    Tang Q; Li S; Huang G; Liu H
    Int Immunopharmacol; 2023 Jun; 119():110158. PubMed ID: 37062259
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enfortumab Vedotin, a fully human monoclonal antibody against Nectin 4 conjugated to monomethyl auristatin E for metastatic urothelial Carcinoma.
    McGregor BA; Sonpavde G
    Expert Opin Investig Drugs; 2019 Oct; 28(10):821-826. PubMed ID: 31526130
    [No Abstract]   [Full Text] [Related]  

  • 18. [Antibody-drug conjugates as new therapeutic agents in uro-oncology].
    Grimm MO; Foller S; Leeder M; Leucht K
    Urologie; 2023 Jul; 62(7):679-684. PubMed ID: 37294330
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Innovations in systemic treatment of urothelial carcinoma].
    Thibault C; Gross-Goupil M
    Bull Cancer; 2020 Jun; 107(5S):S6-S16. PubMed ID: 32620209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Use of enfortumab vedotin in an HIV-positive patient with urothelial carcinoma.
    Azizi A; Houshyar R; Mar N
    J Oncol Pharm Pract; 2022 Jul; 28(5):1226-1229. PubMed ID: 35043748
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.